ClinicalTrials.gg
CompletedNCT01668966Updated May 13, 2019Results posted

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in Brazil. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2019-05-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
95th of 110
23 · median 97
Started
2013
with 8 others
Phase 3
65 of 110
none open now
Registered
66th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 95th largest by enrollment, is one of 9 that started in 2013, is one of 65 in phase 3, and was the 66th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week WA19926 (NCT01007435) core study. Eligible participants will be those who are expected to benefit from the study medicine based on the investigator's discretion.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed their last WA19926 (NCT01649804) core study visit (Week 104) and who may benefit from study drug treatment according to the Investigator's assessment
  • No current or recent adverse event or laboratory finding preventing the use of tocilizumab 8 mg/kg at baseline visit
  • Women of must agree to use highly reliable during the treatment period

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Participants who have withdrawn prematurely from the WA19926 (NCT01649804) core study for any reason
  • Treatment with any agent or cell-depleting therapies since the last administration of study drug in WA19926 (NCT01649804)
  • Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent, or a T-cell costimulation modulator since the last administration of study drug in WA19926 (NCT01649804)
  • Immunization with a live/attenuated vaccine since the last administration of study drug in WA19926 (NCT01649804)
  • Diagnosis since last WA19926 (NCT01649804) visit (Week 104) of rheumatic disease other than RA
  • Diagnosis since last WA19926 (NCT01649804) visit (Week 104) of inflammatory joint disease other than RA
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, including tocilizumab and its
  • Evidence of severe uncontrolled concomitant disease or disorder
  • Known active infections or history of recurrent infections
  • Active tuberculosis requiring treatment in the previous 3 years
  • History of alcohol, drug or chemical abuse since inclusion in the WA19926 (NCT01649804) study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.

    Drug: Tocilizumab

Interventions

  • Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. An SAE can be a) fatal, b) life-threatening, c) requires/prolongs hospitalization, d) results in persistent/significant incapacity/disability, e) results in congenital anomaly/birth defect or f) is considered as a significant medical event by the investigator.

    Time frame: Baseline up to approximately 104 weeks

  2. Percentage of Participants With TEAEs of Special Interest

    An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. Nine categories of AE of special interest are identified for tocilizumab which includes a) serious/medically significant infections, b) myocardial infarction/acute coronary syndrome, c) gastrointestinal perforations, d) malignancies, e) anaphylaxis/hypersensitivity reactions, f) demyelinating disorders, g) stroke, h) serious and/or medically significant bleeding events, and i) serious/medically significant hepatic events. Data reported is an average of the nine categories.

    Time frame: Baseline up to approximately 104 weeks

  3. Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation

    An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started.

    Time frame: Baseline up to approximately 104 weeks

Secondary outcomes

  1. Change From Baseline (CFB) in Disease Activity Score 28 Using Erythrocyte Sedimentation Rate (DAS28-ESR) at Specified Time Points

    The DAS28-ESR is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) (patient global assessment of disease activity \[PGA\] using visual analog scale \[VAS\], range 1-100 millimeters \[mm\]) (higher scores indicate higher disease activity). DAS28-ESR is calculated according to the following formula: DAS28-ESR equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm \[ln\] ESR in mm/h) + (0.014\*GH in mm VAS). DAS28-ESR scale is transformed and ranges from 0 to 10. A negative CFB indicated improvement.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  2. CFB in Simplified Disease Activity Index (SDAI) Score at Specified Time Points

    The SDAI is a combined index for measuring disease activity. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), physician global assessment (PhGA) and PGA of disease activity, both scored 0 to 10 centimeters (cm) as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal is less than (\<) 1 mg/dL. SDAI is calculated according to the following formula: SDAI = TJC + SJC + PhGA + PGA + CRP. SDAI ranges from 0 to 86. A negative CFB indicated improvement.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  3. CFB in Swollen Joint Count (SJC) at Specified Time Points

    For SJC, a total of 66 joints are assessed. The presence of a swollen joint is scored as 1 and absence as 0. Total score is calculated by adding the scores, which ranges from 0 (best possible score or no swollen joint) to 66 (worse possible score or all swollen joints). Lower scores indicated no swollen joint and higher scores indicated worsening swollen joints.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  4. CFB in Tender Joint Count (TJC) at Specified Time Points

    The number of tender joints is recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 68 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  5. Percentage of Participants Reaching Clinical Remission (DAS28-ESR Score Less Than [<] 2.6 and/or SDAI Score Less Than or Equal to [</=] 3.3) Among Participants for Whom Tocilizumab Treatment Was Discontinued

    Remission: DAS28-ESR score \<2.6 and SDAI score \</=3.3. DAS28-ESR index included SJC and TJC, both scored 0-28, as well as APR determined as ESR in mm/hr, and GH (ranges 1-100 mm; higher scores=higher disease activity). DAS28=(0.56\*√TJC)+(0.28\*√SJC) +(0.70\*ln ESR) +(0.014\*GH). DAS28-ESR scale is transformed and ranges from 0 to 10. Negative CFB indicated improvement. DAS28 \>2.6 (clinical remission); DAS28 2.6 to 3.2 (low disease activity); DAS28 \>3.2 to 5.1 = moderate to high disease activity. SDAI is sum of TJC and SJC (both scored 0-28), PhGA and PGA of disease activity (both scored 0 to 10 cm as assessed by VAS, higher scores=higher disease activity), and CRP in mg/dL where normal is \<1 mg/dL. SDAI=TJC + SJC + PhGA + PGA + CRP. SDAI ranged from 0 to 86. A negative CFB indicated improvement. SDAI \<=3.3 (clinical remission), \>3.4 to 11 (low disease activity) \>11 to 26 (moderate disease activity), and \>26 = (high/severe disease activity).

    Time frame: Baseline up to approximately 104 weeks

  6. Time to RA Crisis Among Participants Who Discontinued After Clinical Remission

    RA crisis is any worsening of participant disease acitivity that, in the opinion of the investigator, required intensified treatment other than supportive therapy, and may have included restart of the treatment with the study drug. Time to RA crisis is defined as the period of remission without drug until the RA crisis documentation.

    Time frame: Baseline up to approximately 104 weeks

  7. CFB in PGA of Disease Activity Using VAS Score at Specified Time Points

    PGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative CFB indicated improvement.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  8. CFB in PGA of Pain Using VAS Score at Specified Time Points

    PGA of pain is assessed on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm, and is described as "unbearable pain". A negative change indicated improvement.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  9. CFB in PhGA of Disease Activity Using VAS Score at Specified Time Points

    PhGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

  10. CFB in Health Assessment Questionnaire-Disease Index (HAQ-DI) Score at Specified Time Points

    HAQ-DI is a self-reported participant questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Total score for HAQ-DI is the sum of all questions and ranges from 0 = without any difficulty to 60 = unable to do. A negative CFB indicates improvement.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)

07

Results

Posted May 13, 2019

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started23
Treated21
Completed19
Not completed4
Withdrew: Withdrawal by subject1
Withdrew: Death1
Withdrew: Not treated2

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. An SAE can be a) fatal, b) life-threatening, c) requires/prolongs hospitalization, d) results in persistent/significant incapacity/disability, e) results in congenital anomaly/birth defect or f) is considered as a significant medical event by the investigator.

Time frame:
Baseline up to approximately 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
percentage of participantsTocilizumab
TEAEs95.2
SAEs9.5
PrimaryPercentage of Participants With TEAEs of Special Interest

An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. Nine categories of AE of special interest are identified for tocilizumab which includes a) serious/medically significant infections, b) myocardial infarction/acute coronary syndrome, c) gastrointestinal perforations, d) malignancies, e) anaphylaxis/hypersensitivity reactions, f) demyelinating disorders, g) stroke, h) serious and/or medically significant bleeding events, and i) serious/medically significant hepatic events. Data reported is an average of the nine categories.

Time frame:
Baseline up to approximately 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs of Special Interest
percentage of participantsTocilizumab
Percentage of Participants With TEAEs of Special Interest95.2
PrimaryPercentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation

An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started.

Time frame:
Baseline up to approximately 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation
percentage of participantsTocilizumab
TEAEs leading to study drug discontinuation4.8
TEAEs leading to dose modification28.6
SecondaryChange From Baseline (CFB) in Disease Activity Score 28 Using Erythrocyte Sedimentation Rate (DAS28-ESR) at Specified Time Points

The DAS28-ESR is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) (patient global assessment of disease activity \[PGA\] using visual analog scale \[VAS\], range 1-100 millimeters \[mm\]) (higher scores indicate higher disease activity). DAS28-ESR is calculated according to the following formula: DAS28-ESR equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm \[ln\] ESR in mm/h) + (0.014\*GH in mm VAS). DAS28-ESR scale is transformed and ranges from 0 to 10. A negative CFB indicated improvement.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · units on a scale
Change From Baseline (CFB) in Disease Activity Score 28 Using Erythrocyte Sedimentation Rate (DAS28-ESR) at Specified Time Points
units on a scaleTocilizumab
Baseline (n=21)2.4 ± 1.76
CFB at Week 12 (n=19)-0.6 ± 1.6
CFB at Week 24 (n=21)-0.6 ± 1.7
CFB at Week 36 (n=19)-0.5 ± 1.3
CFB at Week 48 (n=20)-0.6 ± 1.9
CFB at Week 56 (n=19)-0.5 ± 1.7
CFB at Week 68 (n=20)-0.4 ± 2.0
CFB at Week 80 (n=21)0.3 ± 1.9
CFB at Week 92 (n=18)-0.2 ± 1.5
CFB at Week 104 (n=16)-0.7 ± 1.3
CFB at Early withdrawal (n=1)-0.3 ± NA
CFB at Follow-up visit 1 (n=16)0.6 ± 2.1
CFB at Follow-up visit 2 (n=14)1.7 ± 2.0
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.101
  • Tocilizumab · Paired t-test · p = 0.139
  • Tocilizumab · Paired t-test · p = 0.116
  • Tocilizumab · Paired t-test · p = 0.167
  • Tocilizumab · Paired t-test · p = 0.210
  • Tocilizumab · Paired t-test · p = 0.343
  • Tocilizumab · Paired t-test · p = 0.533
  • Tocilizumab · Paired t-test · p = 0.593
  • Tocilizumab · Paired t-test · p = 0.044
  • Tocilizumab · Paired t-test · p = 0.243
  • Tocilizumab · Paired t-test · p = 0.009
SecondaryCFB in Simplified Disease Activity Index (SDAI) Score at Specified Time Points

The SDAI is a combined index for measuring disease activity. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), physician global assessment (PhGA) and PGA of disease activity, both scored 0 to 10 centimeters (cm) as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal is less than (\<) 1 mg/dL. SDAI is calculated according to the following formula: SDAI = TJC + SJC + PhGA + PGA + CRP. SDAI ranges from 0 to 86. A negative CFB indicated improvement.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · units on a scale
CFB in Simplified Disease Activity Index (SDAI) Score at Specified Time Points
units on a scaleTocilizumab
Baseline (n=21)9.5 ± 11.84
CFB at Week 12 (n=20)-2.4 ± 7.75
CFB at Week 24 (n=21)-2.7 ± 11.46
CFB at Week 36 (n=20)-2.8 ± 9.85
CFB at Week 48 (n=20)-3.0 ± 12.71
CFB at Week 56 (n=20)-3.2 ± 11.09
CFB at Week 68 (n=20)-0.6 ± 18.1
CFB at Week 80 (n=21)0.9 ± 13.92
CFB at Week 92 (n=19)-1.1 ± 9.47
CFB at Week 104 (n=19)-1.4 ± 7.6
CFB at Early withdrawal (n=1)-0.3 ± NA
CFB at Follow-up visit 1 (n=19)2.0 ± 12.36
CFB at Follow-up visit 2 (n=14)9.5 ± 16.71
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.1853
  • Tocilizumab · Paired t-test · p = 0.2992
  • Tocilizumab · Paired t-test · p = 0.2249
  • Tocilizumab · Paired t-test · p = 0.3102
  • Tocilizumab · Paired t-test · p = 0.2164
  • Tocilizumab · Paired t-test · p = 0.8822
  • Tocilizumab · Paired t-test · p = 0.7649
  • Tocilizumab · Paired t-test · p = 0.6050
  • Tocilizumab · Paired t-test · p = 0.4478
  • Tocilizumab · Paired t-test · p = 0.4821
  • Tocilizumab · Paired t-test · p = 0.0522
SecondaryCFB in Swollen Joint Count (SJC) at Specified Time Points

For SJC, a total of 66 joints are assessed. The presence of a swollen joint is scored as 1 and absence as 0. Total score is calculated by adding the scores, which ranges from 0 (best possible score or no swollen joint) to 66 (worse possible score or all swollen joints). Lower scores indicated no swollen joint and higher scores indicated worsening swollen joints.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · swollen joints
CFB in Swollen Joint Count (SJC) at Specified Time Points
swollen jointsTocilizumab
Baseline (n=21)0.8 ± 1.7
CFB at Week 12 (n=6)-1.3 ± 1.37
CFB at Week 24 (n=7)-1.6 ± 1.81
CFB at Week 36 (n=6)-1.5 ± 2.81
CFB at Week 48 (n=7)-0.9 ± 3.48
CFB at Week 56 (n=6)-1.8 ± 2.56
CFB at Week 68 (n=7)-2.0 ± 2.38
CFB at Week 80 (n=7)1.1 ± 5.49
CFB at Week 92 (n=6)1.7 ± 5.32
CFB at Week 104 (n=6)1.2 ± 3.82
CFB at Follow-up visit 1 (n=6)-1.3 ± 1.37
CFB at Follow-up visit 2 (n=3)-1.0 ± 0.0
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.0624
  • Tocilizumab · Paired t-test · p = 0.0616
  • Tocilizumab · Paired t-test · p = 0.2480
  • Tocilizumab · Paired t-test · p = 0.5393
  • Tocilizumab · Paired t-test · p = 0.1401
  • Tocilizumab · Paired t-test · p = 0.0679
  • Tocilizumab · Paired t-test · p = 0.6017
  • Tocilizumab · Paired t-test · p = 0.4772
  • Tocilizumab · Paired t-test · p = 0.4877
  • Tocilizumab · Paired t-test · p = 0.0624
  • Tocilizumab · Paired t-test · p = <0.0001
SecondaryCFB in Tender Joint Count (TJC) at Specified Time Points

The number of tender joints is recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 68 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · tender joints
CFB in Tender Joint Count (TJC) at Specified Time Points
tender jointsTocilizumab
Baseline (n=21)5.8 ± 8.57
CFB at Week 12 (n=13)-3.1 ± 8.95
CFB at Week 24 (n=14)-4.8 ± 10.39
CFB at Week 36 (n=14)-5.4 ± 8.35
CFB at Week 48 (n=14)-5.9 ± 8.4
CFB at Week 56 (n=14)-6.0 ± 8.41
CFB at Week 68 (n=13)-2.3 ± 16.51
CFB at Week 80 (n=14)-3.5 ± 11.65
CFB at Week 92 (n=12)-3.6 ± 12.42
CFB at Week 104 (n=12)-4.3 ± 9.98
CFB at Early withdrawal (n=1)0.0 ± NA
CFB at Follow-up visit 1 (n=12)0.0 ± 0.0
CFB at Follow-up visit 2 (n=9)2.4 ± 8.85
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.2388
  • Tocilizumab · Paired t-test · p = 0.1084
  • Tocilizumab · Paired t-test · p = 0.0321
  • Tocilizumab · Paired t-test · p = 0.0203
  • Tocilizumab · Paired t-test · p = 0.0193
  • Tocilizumab · Paired t-test · p = 0.6235
  • Tocilizumab · Paired t-test · p = 0.2814
  • Tocilizumab · Paired t-test · p = 0.3391
  • Tocilizumab · Paired t-test · p = 0.1605
  • Tocilizumab · Paired t-test · p = 0.4312
SecondaryPercentage of Participants Reaching Clinical Remission (DAS28-ESR Score Less Than [<] 2.6 and/or SDAI Score Less Than or Equal to [</=] 3.3) Among Participants for Whom Tocilizumab Treatment Was Discontinued

Remission: DAS28-ESR score \<2.6 and SDAI score \</=3.3. DAS28-ESR index included SJC and TJC, both scored 0-28, as well as APR determined as ESR in mm/hr, and GH (ranges 1-100 mm; higher scores=higher disease activity). DAS28=(0.56\*√TJC)+(0.28\*√SJC) +(0.70\*ln ESR) +(0.014\*GH). DAS28-ESR scale is transformed and ranges from 0 to 10. Negative CFB indicated improvement. DAS28 \>2.6 (clinical remission); DAS28 2.6 to 3.2 (low disease activity); DAS28 \>3.2 to 5.1 = moderate to high disease activity. SDAI is sum of TJC and SJC (both scored 0-28), PhGA and PGA of disease activity (both scored 0 to 10 cm as assessed by VAS, higher scores=higher disease activity), and CRP in mg/dL where normal is \<1 mg/dL. SDAI=TJC + SJC + PhGA + PGA + CRP. SDAI ranged from 0 to 86. A negative CFB indicated improvement. SDAI \<=3.3 (clinical remission), \>3.4 to 11 (low disease activity) \>11 to 26 (moderate disease activity), and \>26 = (high/severe disease activity).

Time frame:
Baseline up to approximately 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Clinical Remission (DAS28-ESR Score Less Than [<] 2.6 and/or SDAI Score Less Than or Equal to [</=] 3.3) Among Participants for Whom Tocilizumab Treatment Was Discontinued
percentage of participantsTocilizumab
Percentage of participants achieved DAS28-ESR <2.6100
Percentage of participants achieved SDAI</=3.3100
SecondaryTime to RA Crisis Among Participants Who Discontinued After Clinical Remission

RA crisis is any worsening of participant disease acitivity that, in the opinion of the investigator, required intensified treatment other than supportive therapy, and may have included restart of the treatment with the study drug. Time to RA crisis is defined as the period of remission without drug until the RA crisis documentation.

Time frame:
Baseline up to approximately 104 weeks
Reported as:
Mean · days
Time to RA Crisis Among Participants Who Discontinued After Clinical Remission
daysTocilizumab
Time to RA Crisis Among Participants Who Discontinued After Clinical Remission135.3 ± 53.73
SecondaryCFB in PGA of Disease Activity Using VAS Score at Specified Time Points

PGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative CFB indicated improvement.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · mm
CFB in PGA of Disease Activity Using VAS Score at Specified Time Points
mmTocilizumab
Baseline (n=21)26.5 ± 19.90
CFB at Week 12 (n=20)-0.3 ± 16.1
CFB at Week 24 (n=21)2.5 ± 23.2
CFB at Week 36 (n=20)2.0 ± 18.5
CFB at Week 48 (n=20)0.4 ± 25.8
CFB at Week 56 (n=20)-0.5 ± 22.1
CFB at Week 68 (n=20)1.3 ± 27.0
CFB at Week 80 (n=21)6.2 ± 27.5
CFB at Week 92 (n=19)3.5 ± 21.6
CFB at Week 104 (n=19)5.1 ± 18.4
CFB at Early withdrawal (n=1)6.0 ± NA
CFB at Follow-up visit 1 (n=17)4.9 ± 22.3
CFB at Follow-up visit 2 (n=14)11.0 ± 29.4
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.934
  • Tocilizumab · Paired t-test · p = 0.624
  • Tocilizumab · Paired t-test · p = 0.642
  • Tocilizumab · Paired t-test · p = 0.952
  • Tocilizumab · Paired t-test · p = 0.928
  • Tocilizumab · Paired t-test · p = 0.832
  • Tocilizumab · Paired t-test · p = 0.315
  • Tocilizumab · Paired t-test · p = 0.485
  • Tocilizumab · Paired t-test · p = 0.246
  • Tocilizumab · Paired t-test · p = 0.375
  • Tocilizumab · Paired t-test · p = 0.185
SecondaryCFB in PGA of Pain Using VAS Score at Specified Time Points

PGA of pain is assessed on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm, and is described as "unbearable pain". A negative change indicated improvement.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · mm
CFB in PGA of Pain Using VAS Score at Specified Time Points
mmTocilizumab
Baseline (n=21)22.3 ± 21.76
CFB at Week 12 (n=20)2.5 ± 14.1
CFB at Week 24 (n=21)5.0 ± 27.7
CFB at Week 36 (n=20)3.6 ± 18.5
CFB at Week 48 (n=20)0.6 ± 26.4
CFB at Week 56 (n=20)1.0 ± 20.0
CFB at Week 68 (n=20)3.7 ± 26.4
CFB at Week 80 (n=21)7.5 ± 28.9
CFB at Week 92 (n=19)2.8 ± 23.4
CFB at Week 104 (n=19)5.8 ± 19.8
CFB at Early withdrawal (n=1)8.0 ± NA
CFB at Follow-up visit 1 (n=17)7.8 ± 24.4
CFB at Follow-up visit 2 (n=14)13.6 ± 29.0
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.445
  • Tocilizumab · Paired t-test · p = 0.414
  • Tocilizumab · Paired t-test · p = 0.401
  • Tocilizumab · Paired t-test · p = 0.920
  • Tocilizumab · Paired t-test · p = 0.834
  • Tocilizumab · Paired t-test · p = 0.539
  • Tocilizumab · Paired t-test · p = 0.246
  • Tocilizumab · Paired t-test · p = 0.602
  • Tocilizumab · Paired t-test · p = 0.218
  • Tocilizumab · Paired t-test · p = 0.208
  • Tocilizumab · Paired t-test · p = 0.101
SecondaryCFB in PhGA of Disease Activity Using VAS Score at Specified Time Points

PhGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · mm
CFB in PhGA of Disease Activity Using VAS Score at Specified Time Points
mmTocilizumab
Baseline (n=21)7.9 ± 11.13
CFB at Week 12 (n=20)-1.0 ± 7.3
CFB at Week 24 (n=21)-0.8 ± 7.7
CFB at Week 36 (n=20)-1.0 ± 8.3
CFB at Week 48 (n=20)0.8 ± 13.1
CFB at Week 56 (n=20)-2.2 ± 9.6
CFB at Week 68 (n=20)1.5 ± 18.1
CFB at Week 80 (n=21)7.6 ± 21.3
CFB at Week 92 (n=19)4.1 ± 13.3
CFB at Week 104 (n=19)5.1 ± 12.2
CFB at Early withdrawal (n=1)-1.0 ± NA
CFB at Follow-up visit 1 (n=19)3.4 ± 9.0
CFB at Follow-up visit 2 (n=14)9.1 ± 17.3
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.565
  • Tocilizumab · Paired t-test · p = 0.637
  • Tocilizumab · Paired t-test · p = 0.594
  • Tocilizumab · Paired t-test · p = 0.788
  • Tocilizumab · Paired t-test · p = 0.329
  • Tocilizumab · Paired t-test · p = 0.716
  • Tocilizumab · Paired t-test · p = 0.119
  • Tocilizumab · Paired t-test · p = 0.201
  • Tocilizumab · Paired t-test · p = 0.087
  • Tocilizumab · Paired t-test · p = 0.116
  • Tocilizumab · Paired t-test · p = 0.070
SecondaryCFB in Health Assessment Questionnaire-Disease Index (HAQ-DI) Score at Specified Time Points

HAQ-DI is a self-reported participant questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Total score for HAQ-DI is the sum of all questions and ranges from 0 = without any difficulty to 60 = unable to do. A negative CFB indicates improvement.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Reported as:
Mean · units on a scale
CFB in Health Assessment Questionnaire-Disease Index (HAQ-DI) Score at Specified Time Points
units on a scaleTocilizumab
Baseline (n=21)4.38 ± 5.463
CFB at Week 12 (n=20)1.60 ± 7.155
CFB at Week 24 (n=21)-0.10 ± 4.560
CFB at Week 36 (n=20)0.05 ± 4.419
CFB at Week 48 (n=20)-1.05 ± 4.199
CFB at Week 56 (n=20)-0.65 ± 4.258
CFB at Week 68 (n=20)-0.40 ± 7.373
CFB at Week 80 (n=21)2.57 ± 10.03
CFB at Week 92 (n=19)1.21 ± 5.855
CFB at Week 104 (n=19)0.21 ± 5.473
CFB at Early withdrawal (n=1)-1.00 ± NA
CFB at Follow-up visit 1 (n=17)0.94 ± 5.226
CFB at Follow-up visit 2 (n=14)3.64 ± 6.344
Statistical analysis
  • Tocilizumab · Paired t-test · p = 0.3299
  • Tocilizumab · Paired t-test · p = 0.9247
  • Tocilizumab · Paired t-test · p = 0.9602
  • Tocilizumab · Paired t-test · p = 0.2773
  • Tocilizumab · Paired t-test · p = 0.5031
  • Tocilizumab · Paired t-test · p = 0.8109
  • Tocilizumab · Paired t-test · p = 0.2540
  • Tocilizumab · Paired t-test · p = 0.3794
  • Tocilizumab · Paired t-test · p = 0.8687
  • Tocilizumab · Paired t-test · p = 0.4685
  • Tocilizumab · Paired t-test · p = 0.0511

Adverse events

Collected over Baseline up to approximately 104 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—2/21 (9.5%)20/21 (95.2%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
Vaginal bleedingReproductive system and breast disorders1/21
BronchopneumoniaRespiratory, thoracic and mediastinal disorders1/21
Cardiac arrhythimiaCardiac disorders1/21
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTocilizumab
Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders9/21
DyslipidaemiaMetabolism and nutrition disorders5/21
Upper respiratory tract infectionInfections and infestations4/21
TracheobronchitisRespiratory, thoracic and mediastinal disorders3/21
Vaginitis BacterialInfections and infestations2/21
Transaminases IncreasedInvestigations2/21
Urinary Tract InfectionRenal and urinary disorders2/21
CoughRespiratory, thoracic and mediastinal disorders2/21
NasopharyngitisRespiratory, thoracic and mediastinal disorders2/21
SinusitisRespiratory, thoracic and mediastinal disorders2/21

Baseline characteristics

Intent to treat (ITT) population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean52.5 ± 9.18
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female15
Male6
08

Study locations

6 sites
  • CIP - Centro Internacional de Pesquisa
    Goiania, GO 74110-120, Brazil
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, MG 36036-330, Brazil
  • Centro de Estudos em Terapias Inovadoras - CETI
    Curtiba, PR 80030-110, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP; Reumatologia
    Sao Paulo, SP 04026-000, Brazil
  • Centro Paulista de Investigacao Clinica - CEPIC
    Sao Paulo, SP 04266-010, Brazil
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in May 2016, 29 months.

Results were first posted in May 2019, 3 years after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 29 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2012
First posted
Aug 20, 2012
StartActual
Dec 9, 2013
Primary completionActual
May 11, 2016
CompletionActual
May 11, 2016
Results first posted
May 13, 2019
Last update
May 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01668966
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 20, 2012
Start date
Dec 9, 2013
Primary completion
May 11, 2016
Completion
May 11, 2016
Results posted
May 13, 2019
Last update
May 13, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion